Environmental

GMED’s R&D intensity of 5.9% of revenue suggests a meaningful innovation footprint, but peer-relative environmental benefits are unclear without disclosed emissions or resource targets.

Very low leverage can support capital flexibility for cleaner operations and compliance investments, yet it does not itself indicate superior environmental management versus medtech peers.

The absence of provided emissions, energy, waste, or climate-transition metrics limits evidence of environmental leadership, leaving GMED closer to the peer middle than top tier.

No post-August 2025 disclosures were provided, so the assessment relies on limited metrics and cannot confirm whether environmental controls outperform similarly sized device peers.

Social

GMED’s R&D-to-revenue ratio indicates sustained product development, which can support patient safety and clinical utility relative to peers with weaker innovation investment.

A gross margin of 68.5% suggests pricing and manufacturing discipline that can help fund training, quality systems, and post-market support, strengthening social resilience.

Low stock-based compensation at 1.6% of revenue implies less dilution-driven incentive pressure, which can align management focus with long-term stakeholder outcomes versus peers.

Limited disclosure on workforce, supply-chain labor, and product-access metrics prevents a higher score, because social leadership cannot be verified against medtech peers.

Governance

GMED’s debt-to-equity ratio of 0.02 and net debt-to-EBITDA of -0.5 indicate conservative balance-sheet governance, which reduces financial stress and oversight risk versus peers.

Stock-based compensation at 1.6% of revenue is modest, suggesting comparatively restrained executive dilution and a cleaner incentive structure than many device peers.

R&D spending at 5.9% of revenue signals disciplined capital allocation toward long-term product development, which is generally favorable for governance quality in medtech.

The lack of disclosed board, audit, ethics, and controversy data prevents an exceptional score, but available capital-discipline metrics place GMED above the peer median.

Overall Score

GMED screens as a strong ESG name versus peers, led by conservative governance and solid social support, while environmental evidence remains limited.

Score Driver: Conservative Capital Discipline And Low Leverage Relative To Peers